Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Brain
2008 Oct 29;1:16. doi: 10.1186/1756-6606-1-16.
Show Gene links
Show Anatomy links
Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies.
Ng FM
,
Geballe MT
,
Snyder JP
,
Traynelis SF
,
Low CM
.
???displayArticle.abstract???
Phenylethanolamines selectively bind to NR2B subunit-containing N-methyl-D-aspartate-subtype of ionotropic glutamate receptors and negatively modulate receptor activity. To investigate the structural and functional properties of the ifenprodil binding domain on the NR2B protein, we have purified a soluble recombinant rat NR2B protein fragment comprising the first ~400 amino acid amino-terminal domain (ATD2B) expressed in E. coli. Spectral measurements on refolded ATD2B protein demonstrated specific binding to ifenprodil. We have used site-directed mutagenesis, circular dichroism spectroscopy and molecular modeling to obtain structural information on the interactions between critical amino acid residues and ifenprodil of our soluble refolded ATD2B proteins. Ligand-induced changes in protein structure were inferred from changes in the circular dichroism spectrum, and the concentration dependence of these changes was used to determine binding constants for ifenprodil and its analogues. Ligand binding of ifenprodil, RO25,6981 and haloperidol on soluble recombinant ATD2B determined from circular dichroism spectroscopy yielded low-to-high micromolar equilibrium constants which concurred with functional IC₅₀ measurement determined in heterologously expressed NR1/NR2B receptors in Xenopus oocytes. Amino acid residue substitutions of Asp101, Ile150 and Phe176 with alanine residue within the ATD2B protein altered the recombinant protein dissociation constants for ifenprodil, mirroring the pattern of their functional phenotypes. Molecular modeling of ATD2B as a clam-shell-like structure places these critical residues near a putative ligand binding site. We report for the first time biochemical measurements show that the functional measurements actually reflect binding to the ATD of NR2B subunit. Insights gained from this study help advance the theory that ifenprodil is a ligand for the ATD of NR2B subunit.
Figure 1. Modular organization of NR2B subunit of NMDA receptor. A. Diagram shows the amino-terminal domain (ATD), the two lobes (S1âS2) comprising the glutamate binding domain, the three transmembrane domains (M1, M3 and M4), the re-entrant loop and the intracellular cytoplasmic terminus (-COOH). ATD has been proposed to harbor the binding site for phenylethanolamines such as ifenprodil. B. Chemical structures of ifenprodil, RO25,6981 and haloperidol â ligands that bind to and negatively modulate the current flux through NR2B subunit-containing NMDA receptors.
Figure 2. Representative CD spectra of soluble 6 à His-ATD2B proteins in the presence and absence of ligands at 25°C. A. Buffer -9 refolded protein; B. Buffer -12 refolded protein; Solid line, protein in absence of ligand; Dotted line, in presence of 5 μM ifenprodil; Dashed line, in presence of 0.5 μM RO25,6981; Dashed-dotted line, 4 M Gdn.HCl-denatured protein. Y-axis represents the molecular ellipticity. X-axis represents the range of wavelengths analyzed.
Figure 3. Ifenprodil and RO25,6981 titration curves of soluble 6 Ã His-ATD2B proteins. A. Buffer -9 refolded protein in the presence of ifenprodil; B. Buffer -12 refolded protein in the presence of ifenprodil; C. Buffer -9 refolded protein in the presence of RO25,6981; D Buffer -12 refolded protein in the presence of RO25,6981. The results are the average of five experiments using proteins obtained from at least two independent batches of bacteria induction. Error bars represent S.E.
Figure 4. Bar chart showing the relative affinities of ifenprodil and RO25,6981 towards the three buffers' refolded 6 à His-ATD2B proteins. A. Results are the average of five experiments using proteins obtained from at least two independent batches of bacteria induction. Error bars represent S.E. Ratios of KD(ifenprodil) to KD(RO25,6981) are 9 (Buffer-9), 15 (Buffer-12) and 24 (Buffer-13), respectively. B. Composite antagonists' inhibition curves are shown for NR1 coexpressed with wild-type NR2B in Xenopus oocytes. Error bars represent ± SEM. C. The Log IC50 for RO25,6981, ifenprodil and haloperidol plotted against their respective Log KD values obtained from dose-titration using CD. A linear regression fit revealed good correlation (R = 0.96) between the mean Log IC50 and Log KD values for each ligand. The mean of the sum of individual log value obtained from each fitted dose-inhibition plot for each ligand and SEM are plotted. Mean KD and IC50 values are given in Table 1.
Figure 5. Ifenprodil titration curve for Buffer -9 refolded wild type and mutant proteins. A. Average dose-titration plots showing reduced affinity of ifenprodil to the F176A mutant protein (n = 5) as compared to the wild type protein (n = 5). The mutant protein harboring double mutations D101A/F176A (n = 5) (open circle) showed further reduction in affinity compared to the single mutant, F176A (filled circle). B. Mutation at residue Asp113, which was identified outside the putative ifenprodil binding pocket by our homology model, did not affect the binding affinity significantly (n = 5, P > 0.4). The KD values for different mutant proteins are listed in Table 2. Each data point is the average value obtained from five experiments using proteins obtained from at least two independent batches of bacteria induction. C. Mean-fitted KD values determined for WT protein and proteins containing the respective mutations. Paired Student t-Tests were performed to evaluate the difference between mean of KD(mutant) and KD(WT), * P < 0.05.
Figure 6. Homology model of ATD of NR2B subunit. A. Ribbon representation of the amino-terminal domain of NR2B was constructed as described under Materials and Methods using mGluR1 crystal structure (1 EWK) as template [36]. Model resembles the clam-shell configuration as seen in the bacterial periplasmic leucine-isoleucine-valine binding protein (LIVBP) (2 LIV). Critical residues (Asp101, Ile150, Phe176) that reduced ifenprodil sensitivity 60-fold and more, when mutated, as compared to wild-type NMDA receptors [23] are shown as red sticks using Rasmol. A mutation (D113A) outside the putative ifenprodil binding pocket is identified by blue sticks. B. Putative ifenprodil binding pocket highlighting the three critical amino acid residues that play critical role in interacting with ligand and the inhibition sensitivity of NR2B-containing NMDA receptors. C. Ifenprodil-docked into ATD2B putative binding pocket model. The relative orientations of side chains of Asp101 (top red residue in red sticks), Ile150 and Phe176 towards the putative centre cleft suggest plausible ligand-protein interactions with various functional groups on ifenprodil (see Discussion).
Arundine,
Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury.
2004, Pubmed
Arundine,
Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury.
2004,
Pubmed
Brimecombe,
An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors.
1998,
Pubmed
Chen,
Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors.
2006,
Pubmed
Chen,
Overexpression of a glutamate receptor (GluR2) ligand binding domain in Escherichia coli: application of a novel protein folding screen.
1997,
Pubmed
Choi,
Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor.
1999,
Pubmed
,
Xenbase
Cull-Candy,
NMDA receptor subunits: diversity, development and disease.
2001,
Pubmed
Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed
Erreger,
Glutamate receptor gating.
2004,
Pubmed
Fayyazuddin,
Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors.
2000,
Pubmed
,
Xenbase
Furukawa,
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
2003,
Pubmed
Furukawa,
Subunit arrangement and function in NMDA receptors.
2005,
Pubmed
Gallagher,
Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor.
1996,
Pubmed
Gerber,
Structural properties of the NMDA receptor and the design of neuroprotective therapies.
2006,
Pubmed
Greenfield,
Circular dichroism analysis for protein-protein interactions.
2004,
Pubmed
Greenfield,
Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions.
2006,
Pubmed
Hardingham,
The Yin and Yang of NMDA receptor signalling.
2003,
Pubmed
Hebenstreit,
Structural changes in calcium-binding allergens: use of circular dichroism to study binding characteristics.
2005,
Pubmed
Heyn,
Circular dichroism and fluorescence studies on the binding of ligands to the alpha subunit of tryptophan synthase.
1975,
Pubmed
Ho,
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
1989,
Pubmed
Horton,
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.
1989,
Pubmed
Ilyin,
Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
1996,
Pubmed
,
Xenbase
Kemp,
NMDA receptor pathways as drug targets.
2002,
Pubmed
Kew,
Ionotropic and metabotropic glutamate receptor structure and pharmacology.
2005,
Pubmed
Kiss,
In vitro characterization of novel NR2B selective NMDA receptor antagonists.
2005,
Pubmed
Kubo,
Structural dynamics of an ionotropic glutamate receptor.
2004,
Pubmed
Kunishima,
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.
2000,
Pubmed
Loftis,
The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications.
2003,
Pubmed
Low,
Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating.
2003,
Pubmed
,
Xenbase
Low,
Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors.
2000,
Pubmed
,
Xenbase
Lynch,
Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes.
2002,
Pubmed
Lynch,
Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit.
2001,
Pubmed
Lynch,
Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors.
1996,
Pubmed
Malherbe,
Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.
2003,
Pubmed
,
Xenbase
Marinelli,
Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding.
2007,
Pubmed
Massey,
Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.
2004,
Pubmed
Masuko,
A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein.
1999,
Pubmed
,
Xenbase
Mayer,
Glutamate receptors at atomic resolution.
2006,
Pubmed
Mayer,
Glutamate receptor ion channels.
2005,
Pubmed
McBain,
N-methyl-D-aspartic acid receptor structure and function.
1994,
Pubmed
McCauley,
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
2004,
Pubmed
McFeeters,
Emerging structural explanations of ionotropic glutamate receptor function.
2004,
Pubmed
Nakagawa,
Structure and different conformational states of native AMPA receptor complexes.
2005,
Pubmed
O'Hara,
The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins.
1993,
Pubmed
Paoletti,
Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit.
2000,
Pubmed
,
Xenbase
Paoletti,
NMDA receptor subunits: function and pharmacology.
2007,
Pubmed
Perin-Dureau,
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
2002,
Pubmed
,
Xenbase
Rachline,
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.
2005,
Pubmed
,
Xenbase
Rosahl,
A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor.
2006,
Pubmed
,
Xenbase
Safferling,
First images of a glutamate receptor ion channel: oligomeric state and molecular dimensions of GluRB homomers.
2001,
Pubmed
Schoemaker,
Binding of [3H]ifenprodil, a novel NMDA antagonist, to a polyamine-sensitive site in the rat cerebral cortex.
1990,
Pubmed
Tichelaar,
The Three-dimensional Structure of an Ionotropic Glutamate Receptor Reveals a Dimer-of-dimers Assembly.
2004,
Pubmed
Traynelis,
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.
1998,
Pubmed
,
Xenbase
Warren,
A critical assessment of docking programs and scoring functions.
2006,
Pubmed
Whittemore,
Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
1997,
Pubmed
,
Xenbase
Williams,
Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
2001,
Pubmed
Williams,
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
1993,
Pubmed
,
Xenbase
Wollmuth,
Structure and gating of the glutamate receptor ion channel.
2004,
Pubmed
Wong,
Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor.
2005,
Pubmed